Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F), 140 (22.7%) had a CALR exon 9 indel, 25 (4.0%) ca...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Rumi, Elisa, Pietra, Daniela, Pascutto, Cristiana, Guglielmelli, Paola, Martínez-Trillos, Alejandra, Casetti, Ilaria, Colomer, Dolors, Pieri, Lisa, Pratcorona, Marta, Rotunno, Giada, Sant’Antonio, Emanuela, Bellini, Marta, Cavalloni, Chiara, Mannarelli, Carmela, Milanesi, Chiara, Boveri, Emanuela, Ferretti, Virginia, Astori, Cesare, Rosti, Vittorio, Cervantes, Francisco, Barosi, Giovanni, Vannucchi, Alessandro M., Cazzola, Mario
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2014
נושאים:
Clinical Trials and Observations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133481/
https://ncbi.nlm.nih.gov/pubmed/24986690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-578435
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים